A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2019
At a glance
- Drugs ACTR707 (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Unum Therapeutics
- 03 Jan 2019 According to an Unum Therapeutics media release, enrollment, dosing and initial clinical data from dose escalation part anticipated in 2019.
- 03 Jan 2019 Status changed from not yet recruiting to recruiting.
- 12 Nov 2018 According to an Unum Therapeutics media release, the design of this study will be discussed at the Investor Event hosted by Unum Therapeutics on Monday November 19, 2018.